Four anti-TIGIT agents, including tiragolumab, vibostolimab, domvanalimab, and ociperlimab34–36, have been evaluated in phase II/III clinical trials in PD-L1-positive patients with non-small cell lung cancer (NSCLC)36, PD-L1-high locally advanced or metastatic NSCLC37,38, locally advanced, unresectable stage III NSCLC, and esophageal squamous cell carcinoma (ESCC), respectively39. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.